 - Context: Oral anticoagulation is recommended for prevention of stroke and thrombo-embolic events in people aged 80 years and over octo suffering from non vavular atrial fibrillation nv AF and without contraindication to anticoagulant therapy. Two drug classes are available to achieve this oral anticoagulation: the vitaminK antagonists VKA, warfarin, fluindione and acenocoumarol or the direct oral anticoagulants DOA, dabigatran, rivaroxaban and apixaban. The data of evidence-based and post-marketing literature on the benefitrisk ratio of DOA comparatively to VKA are limited, conflicting, potentially biased and finally inconclusive in this population. Nevertheless, octo are the age bracket the most at risk for nv AF and the population with the highest risk of both anticoagulant-related major bleedings and AF-related thrombotic TE events. 